Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 10/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 8/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.68 |
| ▸ | HTR1B | P28222 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HRH2 | P25021 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29384552 | 0.98 | HTR1D (0.97) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL11176814 | 0.89 | ADRA2A (0.79) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL17887765 | 0.89 | HTR1D (0.79) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL4761139 | 0.86 | HTR1D (0.75) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL4761560 | 0.86 | HTR1D (0.75) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL11187565 | 0.82 | HTR1D (0.76) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL11157643 | 0.82 | HTR1D (0.68) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL1741885 | 0.81 | ADRA2A (0.77) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| SCHEMBL8020019 | 0.81 | ADRA2A (1.00) | HTR1DADRA2AADRA2CADRA2BADRA1A | |
| Nitric Acid SCHEMBL29355529 | 0.80 | ADRA2A (0.64) | HTR1DADRA2AADRA2CADRA2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116515001-A | Fluorinated cellulose and modification method and application thereof | 海南大学 | 2023-08-01 | — | — | CN | claimed |
| US-20230040339-A1 | THERAPEUTIC AMOEBA AND USES THEREOF | AMEBAGONE, LLC | 2023-02-09 | — | — | US | claimed |
| EP-4081230-A1 | THERAPEUTIC AMOEBA AND USES THEREOF | Amebagone, LLC (US) | 2022-11-02 | — | — | EP | claimed |
| CN-101370500-A | Use of 2-imidazoles for the treatment of CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | claimed |
| EP-1981498-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-la Roche AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | claimed |
| US-5369128-A | Administering a prostaglandin and a peripheral A2 adrenergic agonist | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1994-11-29 | — | — | US | claimed |
| CN-122091550-A | High-performance lithium ion battery anode material Si@void@C@NC and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4745241-A1 | GENE THERAPY VECTOR NUCLEIC ACID CONSTRUCT FOR ALLERGIC DISEASES, AND USAGE METHOD THEREOF | KANGLIN BIOTECHNOLOGY (HANGZHOU) CO., LTD. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-122051255-A | Regular dodecahedron-loaded transition metal catalyst doped with pyridine nitrogen, preparation method and application | 黑龙江大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055137-A | Nanoparticles and formulations thereof for delivery of therapeutic agents throughout the central nervous system | 伊莱利利公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010746-A | Method for preparing aromatic amide by heterogeneous reductive amidation of nitroaromatic hydrocarbon | 中国科学院大连化学物理研究所 | 2026-05-12 | — | — | CN | disclosed |
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-5369128-A | Administering a prostaglandin and a peripheral A2 adrenergic agonist | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1994-11-29 | — | — | US | disclosed |
| US-4025607-A | ANALGESICS, HYPOTENSIVES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-24 | — | — | US | disclosed |
| US-3931216-A | Process for the manufacture of 2-arylamino-2-imidazoline derivatives and their salts | BOEHRINGER INGELHEIM GMBH (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | SLC75A1, SLC18A3, SLC8A1 | HTR1D 1061/4885ADRA2A 811/4885ADRA2C 1299/4885 |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | CRY1, HTR2C, PER2 | HTR1D 52/4885ADRA2A 47/4885ADRA2C 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.